Hematopoietic stem cell transplantation for severe and refractory lupus: Analysis after five years and fifteen patients

Arthritis and Rheumatism

Volumn 46, Issue 11, 2002, Pages 2917-2923

  Traynor, Ann E ^a,b   Barr, Walter G ^a   Rosa, Robert M ^a   Rodriguez, Julianne ^a   Oyama, Yu ^a   Baker, Steven ^a   Brush, Mary ^a   Burt, Richard K ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b Division of Immune Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE STRANDED DNA; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; IMMOBILIZED CELL; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUPUS ERYTHEMATOSUS; LYMPHOCYTE DEPLETION; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PERIOD; REMISSION; SAFETY; SCORING SYSTEM; SERODIAGNOSIS; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREDNISOLONE; SAFETY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0036847280     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10594     Document Type: Article

References (21)

1. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997;6:545-8.
2. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, et al. Treatment of severe systemic lupus with high dose chemotherapy and haemopoietic stem cell support. Lancet 2000;356:701-7.
3. Traynor AE, Burt RK. Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:767-72.
4. Burr RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-14.
5. Burr RK, Traynor A, Ramsey-Goldman R. Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med 1997;337:1777-8.
6. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: Strengths, weaknesses, and opportunities for improvement. Lupus 1999;8:586-95.
7. Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA, for the Lupus Nephritis Collaborative Study Group. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989;36:891-6.
8. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
9. Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, et al. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1996;95:1425-32.
10. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-32.
11. Alarcón-Segovia D, Perez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
12. Wang Y, Schrieber L, Cohen MG, Furphy L, Webb J, Chivers T, et al. Antiphospholipid antibodies in systemic lupus erythematosus: Clinical and laboratory associations in 111 patients. Rheumatol Int 1990;10:75-80.
13. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
14. Zimmerman R, Radhakrishnan J, Valeri A, Appel G. Advances in the treatment of lupus nephritis. Ann Rev Med 2001;52:63-78.
15. Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000;43:1405-9.
16. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:345-51.
17. Ward MM. Hospital experience and expected mortality in patients with systemic lupus erythematosus: A hospital level analysis. J Rheumatol 2000;27:2146-51.
18. Ward MM. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. Am J Kidney Dis 2000;36:516-25.
19. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000;9:166-9.
20. Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: A review of the causes and possible prevention. Hong Kong Med J 2002;8:26-32.
21. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.